IP Library Granted Patent US 7,470,691
Granted Patent B2
US 7,470,691 · App. 11/747,955 · Granted Dec 30, 2008

Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction

Assignee: Abbott Laboratories
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,470,691
App. No.
11/747,955
Granted
Dec 30, 2008
Kind
B2
Abstract

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein A, L, D and B 1 are as described in the specification.

Claims (42)

1. A method of treating male erectile dysfunction in a mammal comprising administering to said mammal in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of

2-{[4-(3-methyl-2-pyridinyl)-1-piperazinyl]methyl}furo[3,2-b]pyridine;

2-[4-(furo[3,2-b]pyridin-2-ylmethyl)-1-piperazinyl]nicotinonitrile; and

2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}furo[3,2-b]pyridine.

2. A method of treating male erectile dysfunction in a mammal comprising administering to said mammal in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of

5-methoxy-2-{[4-(6-methyl-2-pyridinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

5-methoxy-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

2-{[4-(6-methyl-2-pyridinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

2-[4-([1,3]thiazolo[5,4-b]pyridin-2-ylmethyl)-1-piperazinyl]nicotinonitrile; and

2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine.

3. A method of treating male erectile dysfunction in a mammal comprising administering to said mammal in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of

4-(4-{[6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]methyl}-1-piperazinyl)phenol;

2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}-6-(trifluoromethyl)thieno[3,2-b]pyridine;

2-(4-{[6-(trifluoromethyl)thieno[3,2-b]pyridin-2-yl]methyl}-1-piperazinyl)benzonitrile;

4-[4-(furo[3,2-b]pyridin-2-ylmethyl)-1-piperazinyl]phenol;

2-[(4-phenyl-1-piperazinyl)methyl]furo[3,2-b]pyridine;

2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}furo[3,2-b]pyridine;

2-[4-(furo[3,2-b]pyridin-2-ylmethyl)-1-piperazinyl]benzonitrile; and

2-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}furo[3,2-b]pyridine.

4. A method of treating male erectile dysfunction in a mammal comprising administering to said mammal in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of

2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}[1,3]oxazolo[4,5-b]pyridine; and

2-[4-([1,3]oxazolo[4,5-b]pyridin-2-ylmethyl)-1-piperazinyl]benzonitrile.

5. A method of treating male erectile dysfunction in a mammal comprising administering to said mammal in need of such treatment a therapeutically effective amount of a compound is selected from the group consisting of

4-{4-[(5-methoxy[1,3]thiazolo[5,4-b]pyridin-2-yl)methyl]-1-piperazinyl}phenol;

2-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}-5-methoxy[1,3]thiazolo [5,4-b]pyridine;

5-methoxy-2-({4-[2-(methylthio)phenyl]-1-piperazinyl}methyl)[1,3]thiazolo[5,4-b]pyridine;

5-methoxy-2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

2-{[4-(2-chlorophenyl)-1-piperazinyl]methyl}-5-methoxy[1,3]thiazolo[5,4-b]pyridine;

2-{4-[(5-methoxy[1,3]thiazolo[5,4-b]pyridin-2-yl)methyl]-1-piperazinyl}benzonitrile;

2-{[4-(2-chlorophenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

2-{[4-(5-chloro-2-methoxyphenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

4-[4-([1,3]thiazolo[5,4-b]pyridin-2-ylmethyl)-1-piperazinyl]phenol;

2-({4-[2-(methylthio)phenyl]-1-piperazinyl}methyl)[1,3]thiazolo[5,4-b]pyridine;

2-{[4-(2-fluorophenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine;

2-[4-([1,3]thiazolo[5,4-b]pyridin-2-ylmethyl)-1-piperazinyl]benzonitrile;

2-{[4-(2-methoxyphenyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine; and

2-[(4-phenyl-1-piperazinyl)methyl][1,3]thiazolo[5,4-b]pyridine.

6. A method of treating male erectile dysfunction in a mammal comprising administering to said mammal in need of such treatment a therapeutically effective amount of a compound selected from the group consisting of

5-methoxy-2-{[4-(2-pyrimidinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine; and

2-{[4-(2-pyrimidinyl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine.

7. A method of treating male erectile dysfunction in a mammal comprising administering to said mammal in need of such treatment a therapeutically effective amount of

2-{[4-(1,3-thiazol-2-yl)-1-piperazinyl]methyl}[1,3]thiazolo[5,4-b]pyridine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030176/0968 →
Continuity (3)
Division 1044381400 · May 23, 2003
Provisional Application 6038429100 · May 29, 2002
Related Publication 20070265249A1 · Nov 15, 2007